9802321-1

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: A61K 38/05 — A1

(11) International Publication Number: WO 97/12625

(43) International Publication Date: 10 April 1997 (10.04.97)

(21) International Application Number: PCT/US96/15856

(22) International Filing Date: 2 October 1996 (02.10.96)

(30) Priority Data:
08/538,701 — 3 October 1995 (03.10.95) — US
08/614,764 — 13 March 1996 (13.03.96) — US

(60) Parent Application or Grant
(63) Related by Continuation
US — 08/614,764 (CON)
Filed on — 13 March 1996 (13.03.96)

(71) Applicant *(for all designated States except US)*: CYTOVEN J.V. [US/US]; Suite 530, 10230 N.E. Points Drive, Kirkland, WA 98033 (US). See PCT/IB/306

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: GREEN, Lawrence, R. [US/US]; 7506-69th Avenue, S.W., Tacoma, WA 98498 (US). BLASECKI, John, W. [US/US]; 14536-190th Avenue, N.E., Woodinville, WA 98072 (US).

(74) Agents: STORELLA, John, R. et al.; Townsend and Townsend and Crew L.L.P., 8th floor, Two Embarcadero Center, San Francisco, CA 94111-3834 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: PHARMACEUTICAL ANGIOSTATIC DIPEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF

(57) Abstract

Disclosed are methods of inhibiting neovascularization in a subject by administering to the subject a pharmaceutical preparation of R'-Glu-Trp-R".